SCHEMBL15769287

SCHEMBL15769287

CN(c1nc(Nc2ccc(C3CC3)c(C#N)c2)ncc1F)[C@H]1CCCN2CCCC[C@H]12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.38
JAK3 P52333 3/20 0.37
CDK4 P11802 4/20 0.36
PIK3CD O00329 3/20 0.36
CSF1R P07333 3/20 0.36
CDK6 Q00534 3/20 0.36
CCNE1 P24864 3/20 0.36
CDK2 P24941 3/20 0.36
CCNT1 O60563 2/20 0.36
CDK9 P50750 2/20 0.36
FYN P06241 2/20 0.36
AXL P30530 2/20 0.36
CDK1 P06493 2/20 0.36
CCNB1 P14635 2/20 0.36
CCND1 P24385 2/20 0.36
PRKAB2 O43741 1/20 0.36
NUAK1 O60285 1/20 0.36
ABL1 P00519 1/20 0.36
RET P07949 1/20 0.36
PDGFRB P09619 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769976 0.93 CDK1 (0.39) JAK3CDK4PIK3CDCSF1RCDK6
SCHEMBL15769468 0.91 JAK3 (0.45) JAK3CDK4PIK3CDCSF1RCDK6
SCHEMBL15769485 0.90 JAK3 (0.49) JAK3LCKKCNH2
SCHEMBL15769866 0.90 CDK1 (0.36) GRM5JAK3CDK4PIK3CDCSF1R
SCHEMBL15769778 0.90 JAK2 (0.39) JAK3CDK4PIK3CDCSF1RCDK6
SCHEMBL15769875 0.90 JAK2 (0.39) JAK3CDK4PIK3CDCSF1RCDK6
SCHEMBL15769772 0.90 GRM5 (0.39) GRM5JAK3CDK4PIK3CDCSF1R
SCHEMBL15769905 0.89 CDK1 (0.40) CDK4CCNE1CDK2CDK1CCNB1
SCHEMBL15769392 0.88 LRRK2 (0.32) GRM5JAK3CDK4PIK3CDCSF1R
SCHEMBL15769281 0.86 SYK (0.51) GRM5CDK4CCNE1CDK2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB GRM5 3706/4885JAK3 572/4885CDK4 914/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB GRM5 3706/4885JAK3 572/4885CDK4 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.